In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes

被引:1003
作者
Tang, QZ
Henriksen, KJ
Bi, MY
Finger, EB
Szot, G
Ye, JQ
Masteller, EL
McDevitt, H
Bonyhadi, M
Bluestone, JA
机构
[1] Univ Calif San Francisco, UCSF Diabet Ctr, Dept Med, San Francisco, CA 94143 USA
[2] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA
[3] Xeyte Therap Inc, Seattle, WA 98104 USA
关键词
autoimmunity; tolerance; CD4(+)CD25(+)T cells; NOD mice; immunoregulation;
D O I
10.1084/jem.20040139
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The low number of CD4(+) CD25(+) regulatory T cells (T-regs), their anergic phenotype, and diverse antigen specificity present major challenges to harnessing this potent tolerogenic population to treat autoimmunity and transplant rejection. In this study, we describe a robust method to expand antigen-specific T-regs from autoimmune-prone nonobese diabetic mice. Purified CD4(+) CD25(+) Tregs were expanded up to 200-fold in less than 2 wk in vitro using a combination of anti-CD3, anti-CD28, and interleukin 2. The expanded T-regs express a classical cell surface phenotype and function both in vitro and in vivo to suppress effector T cell functions. Most significantly, small numbers of antigen -specific T-regs can reverse diabetes after disease onset, suggesting a novel approach to cellular immunotherapy for autoimmunity.
引用
收藏
页码:1455 / 1465
页数:11
相关论文
共 53 条
[21]   An essential role for Scurfin in CD4+CD25+ T regulatory cells [J].
Khattri, R ;
Cox, T ;
Yasayko, SA ;
Ramsdell, F .
NATURE IMMUNOLOGY, 2003, 4 (04) :337-342
[22]   CD25+CD4+ regulatory T cells prevent graft rejection:: CTLA-4- and IL-10-dependent immunoregulation of alloresponses [J].
Kingsley, CI ;
Karim, M ;
Bushell, AR ;
Wood, KJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (03) :1080-1086
[23]  
Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605
[24]   TRANSFORMING GROWTH FACTOR-BETA-1 NULL MUTATION IN MICE CAUSES EXCESSIVE INFLAMMATORY RESPONSE AND EARLY DEATH [J].
KULKARNI, AB ;
HUH, CG ;
BECKER, D ;
GEISER, A ;
LYGHT, M ;
FLANDERS, KC ;
ROBERTS, AB ;
SPORN, MB ;
WARD, JM ;
KARLSSON, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :770-774
[25]   INHIBITION OF TRANSPLANT REJECTION FOLLOWING TREATMENT WITH ANTI-B7-2 AND ANTI-B7-1 ANTIBODIES [J].
LENSCHOW, DJ ;
ZENG, YJ ;
HATHCOCK, KS ;
ZUCKERMAN, LA ;
FREEMAN, G ;
THISTLETHWAITE, JR ;
GRAY, GS ;
HODES, RJ ;
BLUESTONE, JA .
TRANSPLANTATION, 1995, 60 (10) :1171-1178
[26]   Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice [J].
Lepault, F ;
Gagnerault, MC .
JOURNAL OF IMMUNOLOGY, 2000, 164 (01) :240-247
[27]   Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function [J].
Levings, MK ;
Sangregorio, R ;
Roncarolo, MG .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (11) :1295-1301
[28]   Human CD25+ CD4+ T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells [J].
Levings, MK ;
Sangregorio, R ;
Sartirana, C ;
Moschin, AL ;
Battaglia, M ;
Orban, PC ;
Roncarolo, MG .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (10) :1335-1346
[29]   The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens [J].
Lohr, J ;
Knoechel, B ;
Jiang, SW ;
Sharpe, AH ;
Abbas, AK .
NATURE IMMUNOLOGY, 2003, 4 (07) :664-669
[30]   Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes [J].
Masteller, EL ;
Warner, MR ;
Ferlin, W ;
Judkowski, V ;
Wilson, D ;
Glaichenhaus, N ;
Bluestone, JA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (10) :5587-5595